早期与延迟启动降脂一级预防的预期30年获益
基于NHANES 2009-2016中3148名30-59岁、不符合最新美国指南降脂推荐的人群,模拟立即或延迟降脂对30年动脉粥样硬化性心血管疾病风险的绝对和相对影响。模型A(他汀试验短期效应)和模型B(孟德尔随机化长期获益)均显示,年龄越大、非HDL-C越高,30年风险降低幅度越大;40-49岁且非HDL-C≥160 mg/dL者立即降脂30年,模型A风险从17.1%降至11.6%(ARR 5.5%),模型B降至6.5%(ARR 10.6%),延迟10年或20年则ARR明显缩小。
要点
- 40-49岁非HDL-C≥160 mg/dL者立即降脂30年,模型A绝对风险降低5.5%,模型B降低10.6%。
- 延迟10年降脂(治疗20年)残余30年风险模型A为12.7%(ARR 4.4%),模型B为9.9%(ARR 7.2%)。
- 延迟20年降脂(治疗10年)残余风险模型A为14.6%(ARR 2.6%),模型B为13.9%(ARR 3.2%)。
核心结论
- 对40-59岁非HDL-C≥160 mg/dL者,强化降脂可大幅降低未来30年动脉粥样硬化性心血管疾病预期风险。
- 对许多人而言,何时启动降脂可能比是否启动降脂更值得关注。
研究设计与样本
- 研究分析NHANES 2009-2016中3148名30-59岁、不符合最新美国指南降脂推荐的人群。
- 模型A基于他汀试验短期效应模拟风险降低,模型B基于孟德尔随机化研究长期获益模拟。
主要发现
- 两个模型中,年龄越大、非HDL-C水平越高,预测30年动脉粥样硬化性心血管疾病风险降低幅度越大。
- 40-49岁且非HDL-C≥160 mg/dL者立即降脂30年,模型A风险从17.1%降至11.6%(ARR 5.5%),模型B降至6.5%(ARR 10.6%)。
- 延迟10年降脂(治疗20年)残余30年风险模型A为12.7%(ARR 4.4%),模型B为9.9%(ARR 7.2%)。
- 延迟20年降脂(治疗10年)残余风险模型A为14.6%(ARR 2.6%),模型B为13.9%(ARR 3.2%)。
- ARR随治疗延迟的斜率在年龄更大和非HDL-C更高者中更陡。
临床怎么用
- 对40-59岁非HDL-C≥160 mg/dL且10年风险未达指南降脂阈值者,可考虑早期启动强化降脂以获取长期获益。
- 评估降脂启动时机时,应结合年龄和非HDL-C水平预估30年绝对风险降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lipid-lowering recommendations for prevention of atherosclerotic cardiovascular disease rely principally on estimated 10-year risk. We sought to determine the optimal time for initiation of lipid lowering in younger adults as a function of expected 30-year benefit. METHODS: Data from 3148 National Health and Nutrition Examination Survey (2009-2016) participants, age 30 to 59 years, not eligible for lipid-lowering treatment recommendation under the most recent US guidelines, were analyzed. We estimated the absolute and relative impact of lipid lowering as a function of age, age at initiation, and non-high-density lipoprotein cholesterol (HDL-C) level on the expected rates of atherosclerotic cardiovascular disease over the succeeding 30 years. We modeled expected risk reductions based on shorter-term effects observed in statin trials (model A) and longer-term benefits based on Mendelian randomization studies (model B). RESULTS: In both models, potential reductions in predicted 30-year atherosclerotic cardiovascular disease risk were greater with older age and higher non-HDL-C level. Immediate initiation of lipid lowering (ie, treatment for 30 years) in 40- to 49-year-old patients with non-HDL-C ≥160 mg/dL would be expected to reduce their average predicted 30-year risk of 17.1% to 11.6% (model A; absolute risk reduction [ARR], 5.5%) or 6.5% (model B; ARR 10.6%). Delaying lipid lowering by 10 years (treatment for 20 years) would result in residual 30-year risk of 12.7% (A; ARR 4.4) or 9.9% (B; ARR 7.2%) and delaying by 20 years (treatment for 10 years) would lead to expected mean residual risk of 14.6% (A; ARR 2.6%) or 13.9% (B; ARR 3.2%). The slope of the achieved ARR as a function of delay in treatment was also higher with older age and higher non-HDL-C level. CONCLUSIONS: Substantial reduction in expected atherosclerotic cardiovascular disease risk in the next 30 years is achievable by intensive lipid lowering in individuals in their 40s and 50s with non-HDL-C ≥160 mg/dL. For many, the question of when to start lipid lowering might be more relevant than whether to start lipid lowering.
引用
- Pencina MJ, Pencina KM, Lloyd-Jones D, et al. The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering. Circulation. 2020. PMID: 32700572. doi:10.1161/CIRCULATIONAHA.120.045851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。